Stock Events

Stock Events

Scynexis 

€0.84
0
+€0.01+1.32% Today

Statistics

Day High
0.84
Day Low
0.84
52W High
1
52W Low
0.51
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7MayExpected
Q4 2025
Next
-0.11
-0
0.11
0.21
Expected EPS
-0.1084016186
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 135A.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap153.13B
Pfizer is a global pharmaceutical company that competes with Scynexis in the development of antifungal and antibacterial drugs.
Merck
MRK
Mkt Cap300.2B
Merck & Co., Inc. is involved in the development of anti-infective drugs, directly competing with Scynexis' focus on antifungal treatments.
Gilead Sciences
GILD
Mkt Cap172.51B
Gilead Sciences, Inc. offers antifungal and antiviral therapies, making it a competitor in the infectious disease market.
Astrazeneca
AZN
Mkt Cap316.3B
AstraZeneca PLC has a portfolio that includes anti-infective drugs, competing with Scynexis in the pharmaceutical market.
Johnson & Johnson
JNJ
Mkt Cap574.66B
Johnson & Johnson, through its pharmaceutical division Janssen, develops treatments that compete with Scynexis' drug offerings.
Abbvie
ABBV
Mkt Cap367.8B
AbbVie Inc. competes in the antifungal space with its own range of products, posing competition to Scynexis.
Novartis
NVS
Mkt Cap297.35B
Novartis AG engages in the development of drugs to treat a wide range of infections, including fungal, competing with Scynexis.
AMGEN
AMGN
Mkt Cap189.22B
Amgen Inc. has a diverse biopharmaceutical portfolio that includes treatments for infections, competing with Scynexis.
Bristol-Myers Squibb
BMY
Mkt Cap119.69B
Bristol Myers Squibb has a range of anti-infective drugs, making it a competitor in the same market as Scynexis.
Sanofi
SNY
Mkt Cap113.88B
Sanofi operates in the pharmaceutical sector with a focus on anti-infectives among other areas, competing with Scynexis.

About

SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
Show more...
CEO
Dr. David Gonzalez Angulo M.D.
Employees
28
Country
United States
ISIN
US8112922005

Listings

MU
DE
135A.MU
STU
DE
135A.STU
XNAS
US
SCYX
F
DE
135A.F

0 Comments

Share your thoughts

FAQ

What is Scynexis stock price today?▼
The current price of 135A.MU is €0.84 EUR — it has increased by +1.32% in the past 24 hours. Watch Scynexis stock price performance more closely on the chart.
What is Scynexis stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Scynexis stocks are traded under the ticker 135A.MU.
Is Scynexis stock price growing?▼
135A.MU stock has risen by +9.47% compared to the previous week, the month change is a +10.76% rise, over the last year Scynexis has showed a +10.04% increase.
When is the next Scynexis earnings date?▼
Scynexis is going to release the next earnings report on May 07, 2026.
What were Scynexis earnings last quarter?▼
135A.MU earnings for the last quarter are 0.21 EUR per share, whereas the estimation was 0.11 EUR resulting in a +97.37% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Scynexis have?▼
As of April 14, 2026, the company has 28 employees.
In which sector is Scynexis located?▼
Scynexis operates in the Health & Wellness sector.
When did Scynexis complete a stock split?▼
Scynexis has not had any recent stock splits.
Where is Scynexis headquartered?▼
Scynexis is headquartered in Jersey City, United States.